Citation: | AN Jing, LAO Yun-fei, TANG Song-yuan. Incidence of low-level viraemia among HIV/AIDS patients with antiviral therapy in Yunnan province, 2004 – 2018: a retrospective analysis[J]. Chinese Journal of Public Health, 2022, 38(7): 908-913. doi: 10.11847/zgggws1132975 |
[1] |
中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 国际流行病学传染病学杂志, 2018, 45(6): 361 – 378. doi: 10.3760/cma.j.issn.1673-4149.2018.06.001
|
[2] |
Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society – USA panel[J]. JAMA, 2016, 316(2): 191 – 210. doi: 10.1001/jama.2016.8900
|
[3] |
Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV[EB/OL]. [2020 – 10 – 15].https://api.hiv.plus/uploads/14bcb965d82f4d8da724fb8799644415.pdf.
|
[4] |
European AIDS Clinical Society. European guidelines for treat-ment of hiv infected adults in Europe[EB/OL]. [2020 – 10 – 15].https://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf.
|
[5] |
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection[EB/OL]. [2020 – 10 – 15].https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1.)
|
[6] |
Ping LH, Jabara CB, Rodrigo AG, et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study[J]. PLoS One, 2013, 8(9): e71557. doi: 10.1371/journal.pone.0071557
|
[7] |
Cohen MS, Gamble T, McCauley M. Prevention of HIV transmission and the HPTN 052 study[J]. Annual Review of Medicine, 2020, 71: 347 – 360. doi: 10.1146/annurev-med-110918-034551
|
[8] |
Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy[J]. JAMA, 2016, 316(2): 171 – 181. doi: 10.1001/jama.2016.5148
|
[9] |
Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study[J]. The Lancet HIV, 2018, 5(8): E438 – E447. doi: 10.1016/S2352-3018(18)30132-2
|
[10] |
Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters[J]. The Journal of Infectious Diseases, 2009, 200(6): 984 – 990. doi: 10.1086/605446
|
[11] |
Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure[J]. Clinical Infectious Diseases, 2019, 69(12): 2145 – 2152. doi: 10.1093/cid/ciz129
|
[12] |
Elvstam O, Medstrand P, Yilmaz A, et al. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment[J]. PLoS One, 2017, 12(7): e0180761. doi: 10.1371/journal.pone.0180761
|
[13] |
Charuratananon S, Sungkanuparph S. Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy[J]. Journal of the International Association of Providers of AIDS Care (JIAPAC), 2015, 14(1): 12 – 16. doi: 10.1177/2325957414527168
|
[14] |
Elvstam O, Marrone G, Medstrand P, et al. All-cause mortality and serious non-AIDS events in adults with low-level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish nationwide observational study[J]. Clinical Infectious Diseases, 2020, doi: 10.1093/cid/ciaa413.
|
[15] |
中国疾病预防控制中心性病艾滋病预防控制中心. 国家免费艾滋病抗病毒药物治疗手册[M]. 4版. 北京: 人民卫生出版社, 2016.
|
[16] |
Zhang T, Ding HB, An MH, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort[J]. BMC Infectious Diseases, 2020, 20(1): 147. doi: 10.1186/s12879-020-4837-y
|
[17] |
云南省第三年防治艾滋病人民战争联合评估组. 云南省第三轮防治艾滋病人民战争评估报告[R]. 2016.
|
[18] |
The Antiretroviral Therapy Cohort Collaboration (ART-CC). Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients[J]. AIDS, 2015, 29(3): 373 – 383. doi: 10.1097/QAD.0000000000000544
|
[19] |
Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study[J]. The Lancet Infectious Diseases, 2018, 18(2): 188 – 197. doi: 10.1016/S1473-3099(17)30681-3
|
[20] |
国务院办公厅. 国务院办公厅关于印发中国遏制与防治艾滋病“十三五”行动计划的通知. 国办发〔2017〕8号)[EB/OL]. (2017 – 02 – 05). http://www.gov.cn/zhengce/content/2017-02/05/content_5165514.htm.
|
[21] |
云南省人民政府. 关于印发《云南省第四轮防艾人民战争实施方案(2016 — 2020年)》的通知[R]. (云发[2016]17号), 2016.
|
[22] |
Fleming J, Mathews WC, Rutstein RM, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy[J]. AIDS, 2019, 33(13): 2005 – 2012. doi: 10.1097/QAD.0000000000002306
|
[23] |
Warren AM, Cheng AC, Watson K, et al. Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study[J]. Sexual Health, 2017, 14(3): 238 – 243. doi: 10.1071/SH16165
|
[24] |
Vandenhende MA, Perrier A, Bonnet F, et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study)[J]. Antiviral Therapy, 2015, 20(6): 655 – 660. doi: 10.3851/IMP2949
|
[25] |
Supervie V, Breban R. Brief report: per sex-act risk of hiv transmission under antiretroviral treatment: a data-driven approach[J]. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2018, 79(4): 440 – 444. doi: 10.1097/QAI.0000000000001845
|
[26] |
Yombi JC, Mertes H. Treatment as prevention for HIV infection: current data, challenges, and global perspectives[J]. AIDS Reviews, 2018, 20(3): 131 – 140.
|
[27] |
Iwuji CC, Shahmanesh M, Koole O, et al. Clinical outcomes after first-line HIV treatment failure in South Africa: the next cascade of care[J]. HIV Medicine, 2020, 21(7): 457 – 462. doi: 10.1111/hiv.12877
|